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GeneticsAngiogenesis, the formation of new blood vessels from existing vasculature, is a complex process that is
essential for normal embryonic development. Current models for experimental evaluation of angiogenesis
often use tissue from large vessels like the aorta and umbilical vein, which are phenotypically distinct from
microvasculature. We demonstrate that the utilization of skin to measure microvascular angiogenesis in
embryonic and adult tissues is an efﬁcient way to quantify microvasculature angiogenesis. We validate this
approach and demonstrate its added value by showing signiﬁcant differences in angiogenesis in monogenic
and polygenic mouse models. We discovered that the pattern of angiogenic response among inbred mouse
strains in this ex vivo assay differs from the strain distributions of previous in vivo angiogenesis assays. The
difference between the ex vivo and in vivo assays may be related to systemic factors present in whole
animals. Expression analysis of cultured skin biopsies from strains of mice with opposing angiogenic
response was performed to identify pathways that contribute to differential angiogenic response. Increased
expression of negative regulators of angiogenesis in C57Bl/6J mice was associated with lower growth rates.artment of Health, Albany, NY
n).
ll rights reserved.© 2010 Elsevier Inc. All rights reserved.Introduction
Skin development is a complex process relying on many inter-
acting cell types and homeostatic mechanisms. The epidermis in-
cludes highly proliferative epithelia that acts as a barrier, and a well-
vascularized dermis that can nourish the skin and mediate other
protective mechanisms like thermoregulation and immune response.
The growth of skin microvasculature is tightly regulated and
typically quiescent. However, angiogenesis is rapidly induced to re-
spond to wounding or other developmental perturbations such as hair
follicle growth (Yano et al., 2001). Skin angiogenesis is controlled by
multiple factors that are secreted from keratinocytes, bound to extra-
cellular matrix and produced from within the growing endothelial
cells (Detmar, 2000). Defects in angiogenesis can lead to pathological
states that contribute to diseases including psoriasis rheumatoid
arthritis and cancer (Folkman, 1995).
Vascular endothelial growth factors (VEGFs) are secreted glyco-
proteins that control angiogenesis (Carmeliet and Jain, 2000). When
exposed to VEGF, nascent endothelial cells are induced to degrade
extracellular matrix and grow into the area of neovascularization.
Since its discovery, the VEGF protein family has been the target of
many therapeutic interventions designed to stimulate or repress
angiogenesis. A notable outcome of these therapies is a signiﬁcant
heterogeneity among individuals in response to angiogenesis therapy,which may be due to multiple environmental and genetic factors
(Kerr, 2004). For example, inhibition of angiogenesis can markedly
reduce tumor size (Yuan et al., 1996). Unfortunately, the systemic use
of drugs like bevacizumab, a humanized monoclonal antibody that
binds to VEGF, has been linked to serious side effects including stroke,
heart attack, and intestinal perforations (Ma et al., 2005). Moreover
genetic differences in VEGF and its receptor have been associatedwith
speciﬁc outcomes in anti-angiogenesis drug trials (Schneider et al.,
2008). Thus, while control of angiogenesis has great therapeutic
potential, a more comprehensive understanding of the targeted
pathways is needed to develop safe and effective therapies.
Methodologies to measure angiogenesis range from endothelial
cell assays that are advantageous due to their speed and simplicity, to
in vivo approaches in which additional elements of complexity can be
observed. In particular in vivo approaches are capable of revealing
cell–cell communication that is crucial for normal vessel growth. A
major limitation in the progress of in vivo angiogenesis research is that
measurement of neoangiogenesis is confounded by the presence of
well-developed vascular networks in virtually all mammalian tissues.
Accordingly, evaluation of vessel growth is usually performed after
tissue damage, by inducing ischemia, or wounding. Alternatively,
vessel growth can be followed in avascular media like Matrigel or by
following changes in vessel density in the cornea after surgical
implantation of growth factor infused pellets (Fournier et al., 1981).
Collectively, in vivo angiogenesis assays provide important informa-
tion about the process, but their application is limited by sample-to-
sample variability and the labor-intensive nature. None of the current
assays can be readily applied directly to humans.
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from both neonatal and adult mice. We implemented a semi-
automated quantiﬁcation procedure that measures vessel growth in
the three-dimensional gel matrix. One of the advantages of micro-
vasculature quantiﬁcation is its ability to identify differences in vessel
growth in perinatal-lethal mousemodels with suspected angiogenesis
defects. While validating this method with animal models with
known defects in vessel growth we discovered a pattern of genetic
heterogeneity in angiogenic response that did not correlate with the
genetic pattern seen in studies performed with aortic rings or corneal
implant assays (Rohan et al., 2000). These differences in growth rates
were associated with differences in gene expression that are
potentially responsible for formation of neovessels in skin.
Materials and methods
Mice
Mice were purchased from Jackson Labs, Taconic Farms, or were
bred at the Wadsworth Center. Genetrap ES cells targeting the con-
served helix-loop-helix ubiquitous kinase (Chuck1) were a gift from
Philippe Soriano. Animals were maintained 7 am–7 pm light–dark
cycle with food and water available ad libitum. All procedures were
approved by theWadsworth Center Institutional Animal Care and Use
Committee. Unless otherwise noted, all ex vivo angiogenesis experi-
ments were performed on 3-day-old mice.
Angiogenesis assay
Euthanized 3-day-old mouse pups were weighed, labeled with an
identiﬁcation number that was used to identify the tissue taken from
that animal for subsequent analyses. Mice were soaked in 70% ethanol
for 2 min followed by 10% povidone–iodine solution, and a ﬁnal rinse
in 70% ethanol. Sanitized mice were transferred to Eagle's minimal
essential medium (EMEM) containing 1× Antibiotic–Antimycotic
(Gibco).
Frozen aliquots of the growth factor-reduced basement membrane
matrix, BD Matrigel (BD Bioscience), were thawed on ice for approxi-
mately 1 h. Four10-µldropletswereapplied toa 35-mmFlourodishdish
(WorldPrecision Instruments) andwere spread to approximately 6 mm
in diameter. Matrigel was polymerized at 37 °C/5.0% CO2 for 30 min.
A 2×2 cm full-thickness skin segment was removed with care
from the dorsal ﬂank between the shoulder blades of the mouse and
rinsed with EMEM containing Antibiotic–Antimycotic. A 2 mm biopsy
punch (Miltex) was used to isolate four circular biopsies from each
piece of skin. Each biopsy was placed, dermis side down, on an inde-
pendent Matrigel droplet. An additional 10 µl of Matrigel was layered
over each punch. The dishes were returned to the incubator for a
minimum of 2 h before addition of medium.
The biopsies were fed endothelial cell basal medium 2 (EBM-2,
Lonza) containing 20 ng/ml recombinant human VEGF (R&D Sys-
tems), 2% fetal bovine serum (Sigma), 1× Antibiotic–Antimycotic, and
12.5 µg/µl chloramphenicol (Sigma) for all studies except those
investigating the dose effects of growth factors or serum which were
varied as described in the Results section(see below). Cultures were
maintained for 7 days, with a second feeding approximately 72 h after
the start of the culture.
Vessel quantiﬁcation
Matrigel embedded explants were ﬁxed for 1 h in at 25 °C in 1×
phosphate-buffered saline (PBS) containing 4% paraformaldehyde.
Fixed samples were rinsed three times in 1× PBS and stained with
10 µg/ml Hoechst 33342 stain (Sigma) for 1 h. DNA stain was rinsed
from biopsies and replaced with 1× PBS, and biopsies were held at
4 °C for up to 30 days prior to imaging.Biopsies were visualized with a light microscope (Nikon TE2000,
Melville, NY), equipped for epi-ﬂuorescence (2× 0.1 NA) at and exci-
tation of 340 to 380 nm with UV ﬂorescence collected at 435 to
485 nm. ImagePro 6.2 (Media Cybernetics, Bethesda, MD) was used
to collect a Z-series (70 µm step) with a CCD camera (Roper HQ,
Trenton, NJ). The upper and lower imaging limits were determined
manually by visualization of the uppermost and lowermost stained
nuclei in each biopsy. A maximum local contrast projection was gen-
erated from each image stack by ImagePro 6.2.
Composite images were inspected for any growth irregularities,
including biopsies in which vessels grew to the surface of the Matrigel
and produced a monolayer on the surface of the gel plug, or where the
original biopsy was lost from the Matrigel. Fewer than 1% of the
images were rejected by this criteria. Images exclusively of vessel
growth were then generated the by cropping the skin biopsy from the
composite image by using Photoshop CS3 (Adobe Systems).
Image processing
The 2D grayscale projections (as described above) were converted
to black and white images and then ﬁltered with a Watershed routine
to separate overlapping nuclei. The parameters for both the con-
version to binary and the watershed were optimized to maximize the
quantiﬁcation. The nuclei were then counted, using a size-exclusion
paradigm that minimized the inclusion of non-nuclei objects
(ImagePro 6.2, Media Cybernetics, Bethesda, MD). Speciﬁc settings
are available on request.
Immunohistochemistry
Back skin was taken from the dorsal ﬂank of E18.5 embryos
derived from timed pregnancies between Sfner/+ parents, and ﬁxed in
4% paraformaldehyde (PFA), 30 µm cryosections were blocked in 5%
rabbit serum (Sigma) incubated overnight with a rat anti-CD31
antibody (clone MEC13.3 BD Biosciences) (1:50) at 4 °C, washed in
TBS/0.1% Tween 20, and incubated for 1 h at room temperature with
an Alexa 488-conjugated rabbit anti-rat antibody (1:200) (Invitro-
gen). Slides were mounted with ProLong® Gold Antifade Reagent
(Invitrogen).
Statistics
Statistical signiﬁcance was determined using a Student's t test
for experiments in which control and experimental groups were
being compared, as noted in ﬁgures or text. Statistical signiﬁcance
for multiple means was determined using ANOVA, followed by a
post hoc Tukey's test. A p value of b0.05 was considered to be sig-
niﬁcant. Heritability estimates were calculated by the formula h2=
σg2/σp2, where σg2 equals the genotypic variance of the average of each
strain tested, and σp2 equals the sum of the within-strain phenotypic
variance/total number of strains tested.
In vivo angiogenesis assays
The Directed In Vivo Angiogenesis Assay (Trevigen) was used
according to the manufacturer's directions, with minor modiﬁcations.
Brieﬂy, 20 µl of 200 ng/ml VEGF in growth factor-reduced Matrigel
was added to each angioreactor. Two angioreactors per sidewere then
implanted subcutaneously approximately 1 cm above the hip-socket
in the dorsal ﬂank of each 7-week oldmouse. After 14 days, themouse
was euthanized, and a 2-cm perimeter of skin surrounding the
implantation site was removed. The angioreactors were rinsed brieﬂy
in 1× PBS. A magniﬁed image of the content of each angioreactor was
collected under an Olympus SZX12 dissecting microscope.
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Biopsies growing in glass bottom culture dishes containing green
ﬂuorescent protein-labeled endothelia were imaged with a water-
immersion objective (20×, NA=0.75) using a multi-photon confocal
microscope (Leica SP5, Exton, PA) equipped with a tunable femto-
second pulsed LASER (Mai Tai HP, Spectra-Physics, Mountain View,
CA). For the excitation of EGFP, the pulsed LASER was tuned to
820 nm. Thirty or more optical sections (0.5 μm step) were acquired,
utilizing a non-descanning detector. A maximum intensity projection
composite image was produced from the image stack.
Microarray analysis
Skin biopsies from C57BL/6J mice and FVB/NTAC mice were
cultured as described above for 5 days and rinsed twice in PBS at room
temperature. Eight biopsies per RNA sample were scraped into 1 ml of
Qiazol (Qiagen) and immediately homogenized for RNA extraction,
per the manufacturer's protocol. The aqueous phase was transferred
to RNeasy mini columns and processed according to the manufac-
turer's protocol (Qiagen). RNA integrity was conﬁrmed with the
Agilent Bioanalyzer, which gave a RIN value of N8 for all samples.
One hundred micrograms of total RNA from six independent
samples (three from each strain) was submitted to the Wadsworth
Center Genomics core facility for microarray analysis. Samples were
labeled with the Agilent Low RNA Linear Ampliﬁcation kit according
to the manufacturer's speciﬁcations (Agilent). Cy3-labeled cRNA
targets samples were hybridized to 4X44k mouse genome expression
arrays (14868 Agilent); for all samples, dye incorporation frequency
was N15.
One color-based gene expression normalization and analysis was
carried out using Genespring GX Ver 9.0 with the GCRMA algorithm.
Data were ﬁltered to focus analysis on samples with a present or
marginal ﬂag in at least one sample. Statistical analysis was carried by
an unpaired t test (by strain), and false positives wereminimizedwith
a Benjamini–Hochberg multiple testing correction factor (cutoff
pb0.05).
Quantitative PCR
Expression differences greater than 2-fold were conﬁrmed by
quantitative PCR using Primetime™ qPCR assays (Integrated DNA
technologies). Primer/probe designs are available upon request.
Primers were resuspended according to the manufacturer's recom-
mendations. First strand cDNA was generated with 500 ng of total
RNA isolated as described above using the manufacturer supplied
protocol from the SuperScript III First-Strand Synthesis System
(Invitrogen). cDNAs were diluted 10-fold and real-time PCR was
performed in a 7500 Real-Time PCR System with TaqMan® Universal
PCR Master Mix (Applied Biosystems). Relative expression was
determined using a standard curve generated from a stock cDNA
pool of all samples. Variation in RNA input between samples was
normalized by expressing the results as a ratio of the target cDNA
divided by the amount of 18s target in each sample.
Results
Development of a skin-based microvascular angiogenesis assay
Ex vivo assays with aortic rings from rodents have been utilized to
evaluate angiogenic response in mammals (Masson et al., 2002;
Nicosia et al., 1994). While this approach provides a complex tissue
source that is a good balance of in vivo and in vitro components, it
must be performed on adult animals limiting our ability to evaluate
defects in angiogenesis in animals with perinatal lethality. We
adapted the aortic ring methodology to skin because it is readilyaccessible, and in sufﬁcient quantity to perform multiple assays per
animal. Additionally, we were interested in developing an assay that
evaluated microvasculature to compliment the large vessel data
obtained with the aortic ring assay.
Assays were typically performed on three-day-old mice. This age
was chosen to minimize the effect of hair growth on image acqui-
sition. A 2 cm2 section of full-thickness back skin was isolated from a
euthanized mouse, sanitized in betadine followed by 70% ETOH,
rinsed in EMEM and placed dermis side down to isolate four 2 mm
diameter circular biopsies. Each biopsy was positioned in the center
of a 10 µl drop of growth factor-reduced Matrigel (BD Bioscience),
covered with an additional 10 µl of Matrigel and placed in a 37 °C
humidiﬁed incubator to allow the gel matrix to stabilize. Biopsies
were fed 2.5 ml of endothelial growth medium (EBM-2; Lonza) with
serum, VEGF and basic ﬁbroblast growth factor (bFGF) at various
concentrations (see below) and were maintained in a humidiﬁed
tissue culture incubator at 37 °C with 5% CO2.
After three days in culture, neovessels were observed growing out
of biopsies (Fig. 1a upper frame). Single cell outgrowth progressed
over time to branch into more elaborate structures. By day seven in
culture, well-developed vascular treeswere observed surrounding the
skin biopsies. Growth was sometimes asymmetrical (Fig. 1a lower
panel) possibly indicating that retention of a larger vessel in a biopsy
can inﬂuence growth on a speciﬁc region of a biopsy. Growth beyond
day seven was often associated with vessels reaching the outer edge
of the Matrigel and forming monolayers across the surface of the
Matrigel (data not shown).
To ensure that observed growth was due speciﬁcally to endothe-
lia cell growth rather than ﬁbroblast or keratinocytes, we obtained the
Tg(TIE2GFP)287Sato/J transgenic mouse line that carries a green
ﬂuorescent protein driven by the endothelial cell-speciﬁc receptor
tyorosine kinase promoter (Schlaeger et al., 1997). GFP-positive
vessels were seen within the skin biopsy as well as in the gel matrix
after 7 days of culture (Fig. 1b). Thus, not only were the cells growing
from the skin biopsies endothelial cells, but they were also growing
from existing vasculature, reﬂecting the processes of angiogenesis
in vivo.
Neovessel quantiﬁcation
To quantify vessel growth in the three-dimensional Matrigel
matrix, we developed a semi-automated counting procedure. First,
biopsies were ﬁxed in 4% PFA and stained with 10 µg/ml Hoechst dye
to highlight cell nuclei. A Z-stack of 20× optical slices covering the
entire growth cone of each biopsy was collected under ﬂorescence
and a compositemaximum intensity projectionwas generated (Fig. 1c
upper panel). The image was further processed by digitally removing
the biopsy from the image and converting the remaining image
intensities of outgrowth to either black or white (middle panel). A
series of image ﬁlters were designed to separate overlapping nuclei
and exclude objects outside a predetermined size (Fig. 1c).
Microvessel growth is responsive to serum, bFGF and VEGF
We optimized growth conditions by titrating growth factors
known to affect angiogenesis (Zhu et al., 2003). Robust growth was
observed using fetal bovine serum (FBS) supplemented with VEGF
165 with optimal growth between 2 and 3% FBS (Fig. 2). We then
titrated VEGF and bFGF in 2% FBS. As shown in Fig. 2, VEGF activitywas
maximal between 15 and 20 ng/ml. Basic FGF was more potent than
VEGF showing signiﬁcantly higher growth rates at lower concentra-
tions; however, vessel growth with bFGF beyond three days was
at times associated with keratinocyte migration from the dermal
biopsy (data not shown). This keratinocyte migration inﬂuenced our
quantiﬁcation of neovessels as they were impossible to differentiate
from the vessels. Because keratinocyte migration in response to bFGF
Fig. 1. Examples of skin-based angiogenesis assay. (a) Bright ﬁeld photomicrographs of day 3 and day 7 skin biopsies showing vessel growth surrounding a skin biopsy.
(b) Multiphoton-image of a Tie2-GFP mouse skin biopsy culture. GFP-positive microvessels (arrow) grew out from the pre-existing GFP-positive vessels (arrow) within the skin
biopsy. (c) Quantiﬁcation of the microvessels; ﬁxed skin biopsy cultures were stained with Hoechst dye and 20× 3-dimensional images are collected and converted to a composite
2D image with a ﬂorescent microscope (upper panel). Images are processed (middle panel) and the nuclei of the neovessels are counted with ImagePro as described in Materials and
methods (lower panel).
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2% FBS and 20 ng/ml of VEGF as our standard supplemental growth
factor in our skin biopsy assay.
Skin angiogenesis varies by region in adult skin
Previous assays used to evaluate angiogenesis have demonstrat-
ed substantial variability in vessel growth that has been associated
with the vessel bed being analyzed and environmental variation
within the system (Langenkamp and Molema, 2009). We found
similar levels of variability in our assay as demonstrated by the error
bars in our growth curves (Fig. 2). This variability could be coming
from several sources including the density if the microvascular
plexus within isolated biopsy. We investigated if variations in vessel
growth between different skin regions were present in our assay.
Skin Biopsies from six week old mice were cultured from ears, dorsal
skin, ventral skin and the glaborous skin of the hind paws. Vessel
growth was elicited in all of these tissue regions; however, there was
a ﬁve-fold variation in average vessel growth. Higher responses were
observed in dorsal skin and lower responses from tail skin (Fig. 3a).
While variation within groups was observed, back skin samples
were signiﬁcantly different than ear (pb0.045) foot (pb0.75E−5)
and tail (pb0.57E−9) when comparing 8 independent samples fromtwo mice (Fig. 3a). This ﬁnding indicates that consistent results can
be obtained when care is taken to limit the area samples are taken
from.
Abnormal neoangiogenesis in perinatal-lethal mice
An advantage of the skin biopsy assay is that it can be used to
evaluate defects in vessel growth in mutant strains with postnatal
lethality. For example, the IKKα deﬁcient mice have a perinatal-lethal
phenotype that results in blood in the amniotic ﬂuid (Li et al., 1999;
Takeda et al., 1999). Additionally, conditionally mutant IKKα skin
shows increased vascularity in the dermis compared to wildtype
controls that is associated with increased VEGF-A expression (Gareus
et al., 2007). The phenotypically similar sfner/er mutation is also
associated with perinatal lethality (Herron et al., 2005) but no
signiﬁcant vessel defects have been reported in this mouse model. We
considered the possibility that abnormal vessel growth in the
epidermis could be associated with both the IKKα deﬁcient and
sfner/er phenotypes. Anti-CD31 staining of sfner/er skin revealed blood
vessels within the epidermis (Fig. 3b), while they were restricted
to the dermis in littermate controls. To determine if this defect was
due to abnormal vessel growth, we subjected mutant and normal
littermate controls to our skin biopsy assay. Signiﬁcant differences in
Fig. 2. Titration of growth in skin biopsy cultures. The total average number of endo-
thelial cells growing from 12 skin biopsies was compared with increasing concen-
trations of serum, bFGF and VEGF 165. Higher growth rates in bFGF cultures were
associated with keratinocyte growth from the biopsy (not shown).
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controls on day seven using the ex vivo skin biopsy assay (pb0.015)
validating the ability of this model to detect defects in vessel growth.
Similarly, an IKKα deﬁcient line that was generated from a retroviral
gene trap inserted in the IKKα locus (Chen and Soriano, 2003) showed
signiﬁcantly increased angiogenesis in the skin biopsy assay
(pb0.001) demonstrating the utility of this approach.
In addition to signiﬁcant differences between mutants and litter-
mate controls, differences were present between the wildtype control
strains of their respective mutant backgrounds (Fig. 3c compare
controls C57BL/6J (B6) and FVB/NJ (FVB); pb0.001). Since previous
studies have demonstrated heterogeneity in angiogenic response
among inbred mouse strains (Rohan et al., 2000), we postulated that
similar genetic background effects were modulating the skin biopsy
angiogenesis phenotype.
Skin angiogenic response varies among inbred mouse strains
We determined the extent of differential angiogenic response by
performing a strain survey of inbred mice from separate phylogenetic
arms of commonly used inbred strains (Frazer et al., 2007). Growth
was measured in dorsal skin samples from at least ten individuals
from nine strains of mice; C57BL/6J, BALB/CJ, DBA/2J, I/LnJ, C3H/HEJ,
129X1/SvJ, A/J, FVB/NJ and MRL/MpJ. A three-fold variation in theaverage vessel growth was observed (Fig. 4a). Analysis of variance of
strains (ANOVA) indicated that the observed differences were highly
signiﬁcant (F=9.8892 pb0.0001).
Strains clustered into three groups when the means were com-
pared. The lowest response group comprising C57BL/6J, BALB/cJ and
DBA/2J, were considered to have low angiogenic potential while the
highest response was obtained with the high angiogenic potential
strains A/J, FVB/NJ and MRL/MpJ. The heritability (h2) of the angio-
genic variance between strains was estimated to be 48% of the total
phenotypic variance observed in the assay.
We crossed the low response C57BL/6J (B6) strain to the high
response strains FVB/NJ (FVB) and MRL/MpJ (MRL) to evaluate the
response of F1 offspring. The [B6XFVB]F1 mice had a broad range of
response that was distributed between the parental responses with a
mean that was closer to FVB than B6. While the variance of the
individual [B6XFVB]F1 samples appeared to cover a broader range
than the parental controls the standard error of the [B6XFVB]F1
progeny was comparable to the parental controls (61.9 for F1 versus
56.9 and 87.6 for B6 and FVB respectively) suggesting that the
heritability was consistent in these lines. The average [B6.MRL]F1
response was closer to the B6 parental response indicating an additive
response in this F1 strain combination with dominant alleles residing
in the B6 parental background.
In vitro response does not correlate with in vivo angiogenesis
The distribution of strain responses in the skin biopsy analysis was
not consistent with distributions seen in previous surveys of angio-
genic heterogeneity in inbred mice (Rohan et al., 2000). Comparison
between the in vivo-based corneal implant assay and our ex vivo strain
distributions was poorly correlated (r=0.31; Fig. 5a). The source
of this variability could be coming from several sources. For example,
in vivo assays contain additional sources of variability that could
mediate genetic heterogeneity in VEGF response like circulating
endothelial precursors derived from bone marrow, which have been
proposed to contribute to differential postnatal vasculogenesis in vivo
(Shaked et al., 2005). These effects would not be detected in the skin
biopsy assay. Alternatively, genetic differences between the subcuta-
neous vasculature and the limbal vasculature of the cornea could be
causing the differential response between these assays (Langenkamp
andMolema, 2009). Vessel growth in subcutaneous Matrigel implants
was measured in B6, FVB and 129 mice to determine if subcutaneous
vessels have a different growth response when measured in an in vivo
system (Guedez et al., 2003). Qualitative differences in vessel growth
between B6, FVB and 129 mice were detected that were consistent
with the corneal implant assay. The largest amount of growth was
seen in the 129 implants (Fig. 5b), where seven of eight implants
displayed visible vessel growth and hemoglobin within the implants.
Four of eight implants showed growth in FVB, while B6 implants
exhibited visible growth in only one of eight implants. Thus, the
subcutaneous in vivo ﬁndings were consistent with the corneal
implant assay, supporting the hypothesis that additional systemic
factors contribute to angiogenesis in vivo.
Differences in angiogenic response correlate with differences in gene
expression
We considered the possibility that the basis of differential angio-
genic response between B6 and FVBmice may be due to differences in
vessel densities within the biopsies prior to culture. Greater densities
of vessels in the FVB biopsies could lead to higher growth rates in
biopsies from this strain. We measured the relative amount of vessels
within biopsies prior to culture by performing quantitative PCR on
cDNA generated from individual biopsies from B6 and FVB skin. The
endothelia-speciﬁc markers platelet endothelial cell adhesion mole-
cule (CD31) and Cadherin 5 (Cdh5)were used as surrogate markers to
Fig. 3. (a) Skin biopsies from seven-week-old ears, dorsal skin, ventral skin, tail skin and the glaborous skin of the hind paws were compared for relative growth rates after 7 days in
culture (n=8). Average response is presented +/−standard error. (b) Confocal micrographs of skin from sfnEr/Er and WT control mice showing abnormal vessel growth in mutant
skin. Blood vessels were stained with anti-CD31 antibody (green) and nuclei were stained with DAPI (blue). The basement membrane is highlighted by a dashed line. Blood vessels
normally only present in the dermis layer of the skin, were extended into the epidermis layer in Sfner/er mice (arrowheads). (c) Skin biopsies from both SfnEr/Er and IKKα deﬁcient
embryos had higher rates of angiogenesis than WT controls on the same background (n≥6).
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31 and Cdh5 was slightly lower in FVB (CD31/18s ratio 1.1+/−0.39
Fig. 6a) than B6 (1.5+/−0.44) but the difference did not achieve
statistical signiﬁcance (p=0.162) and similar results were obtained
for Cdh5 (Fig. 6a). Thus, the variance between these strains is not
directly related to baseline differences in vessel density.
Differential expressions of many genes have been implicated
in differential angiogenic response. We performed genome-wide
expression analysis to determine whether any major pathways or
genes previously linked to angiogenesis were differentially regulated
in our system. We chose to compare B6 explants to FVB explants
during the 5th day of culture because the maximal differences in
vessel growth were detected between them on day ﬁve.Expression proﬁles were generated from FVB and B6 skin biopsies
with Agilent Whole Mouse Genome Oligo Microarrays. More than
900 genes were signiﬁcantly altered (1.8-fold or greater differen-
tial expression after multiple testing correction; pb0.05 (data not
shown)).
We focused our attention on genes previously associated with
angiogenic activity by limiting our comparison to the genes expressed
in our tissue that were listed under the gene ontology category
“angiogenesis” and “vessel development” (see: GO IDs 0001525 and
0001568). Therewere 118 genes from the two categories expressed in
our dataset. Among this subset, 23 transcripts were signiﬁcantly
altered in expression, with 8 showing greater than a twofold
expression difference (Table 1).
Fig. 4. Genetic heterogeneity of skin angiogenic response. (a) Angiogenic responses of
different inbred mouse strains revealed a three-fold variation in the average vessel
growth. Bars indicate the mean and standard error of multiple experiments (n≥10).
(b) Comparing the low response strain B6 to the sensitive strains FVB and MRL
demonstrated that most of the variance was due to genetic background. While average
vessel growth per animal (black dots) showed environmental variance within each
strain, the 95% conﬁdence interval for the strains (green diamonds) was consistent with
two groups. [B6XFVB]F1s were most similar to FVB response while the [B6XMRL]F1
progeny were most similar to B6 (Tukey–Kramer test, p=0.05) suggesting that distinct
genetic factors weremediating angiogenic responses in the F1 hybrids consistent with a
complex trait model.
Fig. 5. In vivo angiogenic responses between FVB, B6 and 129X1. (a) Comparison of
respective strains (X axis) to VEGF stimulated angiogenic responses in the ex vivo skin
biopsy assay (Y axis right blue circles) to the in vivo corneal implant assay ((Shaked
et al., 2005) Y axis left red squares). Trend lines across strain responses demonstrate the
poor correlation between these assays. (b) Matrigel ﬁlled tubes were subcutaneously
implanted in four adult mice per strain for 14 days. Minimal neovascularization is
observed in the C57BL/6J mice as indicated by the blood-ﬁlled neovessels in the
implant furthest to the right (top panel) followed by FVB/NJ (middle panel) showing
three implants with red vessels and ﬁnally 129X1/SVJ with the highest amount of
vessel innervations (6 implants, bottom panel).
486 F. Liu et al. / Developmental Biology 340 (2010) 480–489We conﬁrmed the expression differences that were greater than
2-fold between samples from the micro array analysis (Fig. 6b) with
quantitative PCR. Triplicate samples from B6 and FVB skin biopsies
were grown until day 5 and cDNAs were generated and used to
perform TaqMan assays. The total amount of transcript in each
sample was normalized to 18s transcript levels. While all targets
tested had expression differences that were consistent with the
direction of the B6 versus FVB results obtained from the microarray,
only three achieved a signiﬁcance of pb0.05; Epiregulin, thymus cell
antigen 1 and thrombospondin 1.
Discussion
We describe a novel method for quantiﬁcation of angiogenesis
using skin biopsies isolated frommice that is designed to complement
existing methods. This approach combines the complex tissue inter-
actions of in vivo assays with the speed and enhanced ability to
quantify growth of in vitro systems. While the ex vivo aortic ring assay
evaluates large vessels the skin biopsy assay is focused on growth in
microvasculature.
The skin is a readily accessible abundant tissue that is well-
developed in later embryonic stages. These qualities help our method
in several ways. Minimal experimental manipulation leads to more
consistent results, multiple samplings from each individual reduces
the impact of environmental variation and the ability to evaluate
embryonic tissue alleviates lethality that is often associated with
vascular defects in mammals.
We also demonstrate that this assay can be performed on adult
tissues. This approach should beneﬁt the measurement of angio-
genesis in models where vessel growth needs to be measured after
therapeutic intervention. A notable application of this approach is that
since it is minimally invasive, it therefore could potentially be per-formed on humans. This places the skin biopsy assay in a unique
position to be used to assess the angiogenic potential of individuals
prior to the administration of angiogenic therapy.
Considering the relatively short time frame of this analysis (1 to
7 days) the procedure is most likely identifying early events in the
angiogenic process including endothelial cell proliferation, migration
and cell survival. Later events like vessel maturation, tube formation
are better suited for in vivo approaches.
By developing a semi-automated counting procedure, we sought
to maximize quantiﬁcation, limit observational bias and increase
throughput. Quantiﬁcation of the total number of cells, rather than
tracing vessel outgrowth to determine its volume was considered a
more sensitive measure of angiogenesis. Samples with large amounts
of growth were incompletely quantiﬁed when tracing growth rings in
two dimensional images (data not shown). Through the use of low
magniﬁcation ﬂorescent Z-stacked series in conjunction with image
Fig. 6. Differential expression in B6 and FVB mice related to angiogenesis. (a) The
average vessel density of isolated skin biopsies from B6 and FVB mice (n=8 biopsies/
strain) was estimated by determining the expression level of Cdh5 and CD31 by
quantitative PCR normalized to 18s RNA. (b) Messenger RNA isolated from samples of
B6 and FVB skin biopsies cultured for 5 days was measured for expression differences in
genes previously implicated in angiogenesis discovered from global gene expression
analysis (see Table 1). Columns with double asterisks indicate that the differential
expression achieved a signiﬁcance level of pb0.05.
487F. Liu et al. / Developmental Biology 340 (2010) 480–489processing techniques we could reproducibly demonstrate quantita-
tive differences in angiogenesis that accounted for growth in three
dimensions.
Skin angiogenesis was shown to be responsive to increasing
concentrations of serum, VEGF and bFGF. While keratinocytes are
migratory in the presence of any these factors, we found at doses up
to 4% serum, and 15 ng/ml VEGF, that more than 95% of biopsy
outgrowth was positive for blood vessel markers for up to 10 days.
The presence of Matrigel was also required for vessel growth whileTable 1
Expression differences between C57BL/6J and FVB/NJ related to vessel development (great
Unigene ID Gene symbol Gene name
NM_010228 Flt1 Fms-like tyrosine kinase 1
NM_016678 Reck Reversion-inducing-cysteine-rich protein with kaz
NM_008592 Foxc1 Forkhead box C1
NM_009382 Thy1 Thymus cell antigen 1, theta
NM_013630 Pkd1 Polycystic kidney disease 1 homolog
NM_007856 Dhcr7 7-dehydrocholesterol reductase
NM_007950 Ereg Epiregulin
NM_001039087 Rapgef1 Rap guanine nucleotide exchange factor (GEF) 1
NM_027462 Wars2 Tryptophanyl tRNA synthetase 2 (mitochondrial
NM_010303 Gna13 Guanine nucleotide binding protein, alpha 13
NM_011580 Thbs1 Thrombospondin 1
NM_009406 Tnni3 Troponin I, cardiac
NM_009621 Adamts1 A disintegrin-like and metallopeptidase (reprolysin
NM_008608 Mmp14 Matrix metallopeptidase 14 (membrane-inserted)
NM_009505 Vegfa Vascular endothelial growth factor A
AK122317 Jmjd6 Jumonji domain-containing protein 6
AK018789 Ntrk2 Neurotrophic tyrosine kinase, receptor, type 2
NM_008827 Pgf Placental growth factor
NM_194054 Rtn4 Reticulon 4only limited response was observed in collagen gels, which has been
reported to support the growth of vessels from aortic rings of adult
animals (Nicosia and Ottinetti, 1990). Ongoing experiments will
address alternative matrix materials that can be used in our assay.
While variation between samples taken from different skin regions
of the same animal was observed, we found that good reproducibility
could be achieved by performing multiple assays per animal in the
same region. When using three-day-old mice we found little dif-
ference between dorsal and ventral skin angiogenic potential. How-
ever, adult skin from the densely haired regions produced more
vessels than did the tail and ears where skin could be seen. While
previous work has associated increases in angiogenesis with active
hair growth (Yano et al., 2001), the adult mice used in this study were
in the resting phase of the hair cycle. The increased vessel growth in
haired skinmay reﬂect a larger pool of intrinsic endothelial progenitor
cells that are present to sustain the skin during anagen hair growth or
may be a direct result of skin thickness.
An advantage of our approach as compared to other ex vivo assays
is the ability to test for defects in angiogenesis when the animals do
not survive to adulthood. The conditional inactivation of IKKα in the
skin has previously been shown to increase vessel density (Gareus
et al., 2007). This phenotype is associated with increased VEGF
expressing in keratinocyte and we show here that this mutation has a
direct impact on dermal vessel growth. The phenotypically similar
recessive Repeated Epilation mutant was previously reported to have
a similar but less severe vessel phenotype (Fisher, 2000). We demon-
strate here that skin biopsies from Sfner/er embryos have increased
angiogenic response when compared to littermate controls but these
differences were not as signiﬁcant as the IKKα deﬁcient skin biopsies
consistent with a more severe angiogenesis defect in IKKα deﬁcient
mice.
The elevated angiogenic response of Sfner/er mice, which have a
mutation in the 14-3-3 protein stratiﬁn (Herron et al., 2005), is of
particular interest because Sfn is repressed in several human cancers
(Hermeking et al., 1997). While much of the focus on Sfn's function to
date has been related to cell-cycle control, our results may indicate
that Sfn expression could also enhance the ability of the stroma to
induce angiogenesis in the growing tumor. Since Sfn is expressed from
keratinocytes and is not detectable in endothelial cells (Kilani et al.,
2008) the differences in angiogenesis are likely due to epithelial/
mesenchymal interactions.
In addition to the responses of Sfn and IKKα deﬁcient lines we
found signiﬁcant differences in angiogenesis among inbred strains. In
particular, we identiﬁed three strains with enhanced vessel response;er than 2 fold in bold).
p value B6/FVB fold change
4.04E−04 2.29
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healing capacity that is under genetic control (Clark et al., 1998).
Wound healing in MRL mice has been linked to multiple genomic
regions (quantitative trait loci (QTL)) but our analysis is the ﬁrst
demonstration that enhanced angiogenesis is a component of
enhanced wound healing in MRL mice. It will be of interest to look
more closely at the previously mapped HEAL QTLs (McBrearty et al.,
1998; Yu et al., 2005) to determine if angiogenesis is speciﬁcally
responsible for the wound response phenotype at any of these
regions.
While the FVB strain is best known for its qualities that make it
useful for the production of transgenic animals it also possesses
additional phenotypic traits that reﬂect its sensitivity to VEGF-
induced angiogenesis. The FVB strain is sensitive to two-stage
chemically induced skin carcinogenesis and MMTV driven breast
cancer (Hennings et al., 1993; Le Voyer et al., 2000). The later of
these two phenotypes has been directly linked to microvessel
density of the tumors (Le Voyer et al., 2001). Additionally FVB mice
are susceptible to asthma (Whitehead et al., 2003) a complex trait in
which angiogenesis has been implicated in disease progression
(Charan et al., 1997).
The strain distributions of the skin biopsy assay did not correlate
with other angiogenesis assays (Rohan et al., 2000; Zhu et al., 2003).
Zhu et al., using the aortic ring assay, were able to demonstrate
differences in angiogenic potential that were both strain and age
dependant. The corneal implant assay also displayed broad genetic
heterogeneity when it was performed on various inbred strains.
Notably, the distribution of strains did not correlate between these
different assays. For example, while the FVB strain was the highest
responder in the skin biopsy assay, it was a low responder in the aortic
ring and corneal implant assays. The differences between the aortic
ring and skin biopsy assays may reﬂect the biological differences
between large vessels and microvasculature.
The differences between the in vivo and in vitro assays could be due
to additional systemic effects that contribute to the differential
angiogenic response in vivo. This hypothesis is supported by recent
studies investigating the source for the blood vessel precursor cells.
Circulating peripheral blood endothelial cells (CECs) and their
progenitors are thought to have a signiﬁcant impact on the body's
ability to induce neoangiogenesis (Carmeliet and Luttun, 2001).
Shaked et al. were able to show a correlation between strain angio-
genic phenotypes (based on corneal micropocket assay) and the total
number of circulating CECs and/or CEPs (Shaked et al., 2005). Thus, a
potential explanation for the high angiogenic response in 129 mice is
that there is a larger pool of CECs or CEPs with which to mount an
increased angiogenic response. Because our in vitromodel eliminates
the potential contribution of CECs or CEPs, this factor cannot con-
tribute to differences detected in vitro.
The identiﬁcation of the genetic differences that contribute to
angiogenesis will beneﬁt from approaches that can focus on speciﬁc
aspects of angiogenesis that are likely to be controlled by fewer genes
than more complex models. The skin biopsy assay is tractable in this
respect not only because it reﬂects fewer variables relevant to early
stages of angiogenesis, but also because it can be performed on
neonatal mice. Thus, the large crosses required for mapping QTLs
would require minimal husbandry and expense when compared to
other methods.
Using a Matrigel implant assay, we were able to conﬁrm that
subcutaneous vasculature of 129 mice was capable of a robust angio-
genic response that was higher than the response that was noted in
the skin biopsy assay. This result indicates that the 129 response in the
corneal micropocket assay is not tissue-speciﬁc.While a systemic pool
of endothelial progenitor cells may in part describe the differences
between the ex vivo and in vivo responses, differences in inﬂammatory
response between inbred strains and many other factors could also
contribute to in vivo responses.The genetic diversity we discovered in angiogenesis was also
reﬂected in the transcriptome of divergent strains. Analysis of genes
previously implicated in vessel formation that were included in the
gene ontology categories “vessel development” and “angiogenesis”
demonstrated that multiple signaling pathways may be altered in
these strains. Surprisingly, genes that are considered to be proangio-
genenic like VEGF and Pgf were expressed at higher levels in low
growth strain C57BL6/J; however, the ratio of these differences was
not as large as other notable differences. Since angiogenesis is con-
trolled by a balance of pro and anti angiogenic signals some of these
differences may represent secondary consequences of ongoing vessel
growth.
Further conﬁrmation of the expressed differences greater than 2
fold by quantitative PCR reduced the list of signiﬁcantly differentially
expressed differences to three genes, Epiregulin, thymus cell antigen 1
and thrombospondin 1. While the direction of all of the other tested
genes had differences that corresponded with the microarray results
they did not achieve signiﬁcance. Thombospondin one (Thbs1) over
expression in B6 skin is consistent with the lower growth observed in
this strain. This heterotrimeric adhesive glycoprotein is thought to
mediate cell–matrix interactions and has demonstrated antiangio-
genic activity in multiple studies (Armstrong et al., 2002; Iruela-
Arispe et al., 1991; Taraboletti et al., 1990). Increased expression
of Thbs1 in conjunction with other antiangiogenic factors like Flt 1
(Fuh et al., 2000) could potentially repress the growth of vessels in B6
biopsies. Tissue homeostasis and remodeling that is dependent on
Thbs1 require Thy-1 surface expression which is supported by the
correspondingly high Thy 1 expression in B6 mice skin in this model
(Abeysinghe et al., 2003). While thy-1 expression in vivo promotes
angiogenesis via increased endothelial permeability and inﬂamma-
tion, our ex vivo assay would not be responsive to these effects.
Conversely, over expression of Epiregulin (Ereg), a potent stimulator
of angiogenesis, in FVB skin will further stimulate vessel growth
in this strain. Increased Ereg expression has been associated with
psoriasis in humans (Shirakata et al., 2007). However the ultimate
role of these expressed differences in the ongoing genetic heteroge-
neity in inbred strains awaits themapping and eventual cloning of the
underlying mutations.
In conclusion, the skin biopsy assay is a powerful tool to evaluate
the efﬁcacy of pro- and anti-angiogeneic agents. This model has
distinct responses from in vivo and other ex vivo assays suggesting
that it is an important alternative approach for the evaluation of
factors that mediate angiogenesis in mammals.Acknowledgments
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